622-P: Role of Mindfulness in the Quality of Life and Promotion of Well-Being in Type 1 Diabetic Patients

Le résumé fourni par la source

Introduction and Objective: Mindfulness is a meditation focused on awareness of present moment, encouraging open, curious, and non-judgmental observation of one's personal experience. The Mindfulness-Based Stress Reduction (MBSR) program is used in hospital settings. Primary objective was to evaluate the impact of the MBSR program on quality of life in type 1 diabetic patients. Secondary objectives: to evaluate the impact on diabetes related stress, depression, satisfaction with diabetes therapy and psychopathological symptoms. Methods: Retrospective observational study of 33 type 1 diabetic patients (13 with traditional pumps, 20 with MDI). Psychological aspects were assessed at beginning of the program (T0) and at the end (T1), with: Audit of Diabetes-Dependent Quality of Life(ADDQoL); Problem Areas In Diabetes(PAID-5); Beck depression inventory(BDI); Diabetes Treatment Satisfaction Questionnaire(DTSQ); Symptom CheckList 90(SCL-90). The protocol was approved by local ethics committee. Wilcoxon signed-rank test was used for paired data, and linear regression models assessed associations between pre/post. Results: Regarding quality of life, significant improvements were observed in items related to family life and physical appearance (p=0.007 and p=0.02). Diabetes-related stress, measured with PAID-5, showed reductions in both total scores and subitems (p=0.003, p<0.01). Total scores and subitems of BDI and SCL-90 also decreased (p<0.001). HbA1c levels improved in patients using traditional pumps (p<0.03), in those with high school diploma (p=0.02), in those with increased importance of physical appearance (p<0.001) and in those with a reduction in diabetic related stress (p=0.02). Conclusion: Mindfulness might improve quality of life, reduce depression, stress, and psychopathology, supporting well-being in type 1 diabetic patients. Disclosure E. Resmini: None. V. Turra: None. Y. Jin: None. A.V. Cornaghi: None. M. Sandri: None. E. Cimino: Speaker's Bureau; roche, Abbott. E. Zarra: None. C. Mascadri: None. G. Massari: None. S. Madaschi: None. B. Pasquino: None. M. Migazzi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.